Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
Cue Biopharma (Nasdaq: CUE) announced its participation in a fireside chat at the Citizens Life Sciences Conference in New York on May 8, 2025. CEO Daniel Passeri will present from 11:00 AM to 11:25 AM EDT, discussing progress on the company's Immuno-STAT鈩� platform programs, including the CUE-100 series, CUE-401, and CUE-501. The presentation will highlight their recent partnership with Boehringer Ingelheim for CUE-501, focusing on T cell mediated targeted depletion of specific B cells for treating autoimmune and inflammatory diseases. A live webcast will be available, and the recording will be archived for 30 days on the company's website.
Cue Biopharma (Nasdaq: CUE) ha annunciato la sua partecipazione a una conversazione informale al Citizens Life Sciences Conference a New York il 8 maggio 2025. Il CEO Daniel Passeri presenter脿 dalle 11:00 alle 11:25 EDT, illustrando i progressi dei programmi basati sulla piattaforma Immuno-STAT鈩�, inclusi la serie CUE-100, CUE-401 e CUE-501. La presentazione metter脿 in evidenza la recente collaborazione con Boehringer Ingelheim per CUE-501, focalizzata sulla deplezione mirata di specifiche cellule B mediata da cellule T per il trattamento di malattie autoimmuni e infiammatorie. Sar脿 disponibile una diretta webcast e la registrazione rester脿 archiviata per 30 giorni sul sito web dell'azienda.
Cue Biopharma (Nasdaq: CUE) anunci贸 su participaci贸n en una charla informal en la Citizens Life Sciences Conference en Nueva York el 8 de mayo de 2025. El CEO Daniel Passeri presentar谩 de 11:00 a 11:25 AM EDT, hablando sobre los avances en los programas de la plataforma Immuno-STAT鈩�, incluyendo la serie CUE-100, CUE-401 y CUE-501. La presentaci贸n destacar谩 su reciente asociaci贸n con Boehringer Ingelheim para CUE-501, enfocada en la depleci贸n espec铆fica de c茅lulas B mediada por c茅lulas T para tratar enfermedades autoinmunes e inflamatorias. Habr谩 una transmisi贸n en vivo y la grabaci贸n estar谩 disponible durante 30 d铆as en el sitio web de la compa帽铆a.
Cue Biopharma (雮橃姢雼�: CUE)电� 2025雲� 5鞗� 8鞚� 雺挫殨鞐愳劀 鞐措Μ电� Citizens Life Sciences Conference鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO 雼る媹鞐� 韺岇劯毽鐢 霃欕秬鞁滉皠 旮办 鞓れ爠 11鞁滊秬韯� 11鞁� 25攵勱箤歆� Immuno-STAT鈩� 頂岆灚韽� 頂勲攴鸽灗鞚� 歆勴枆 靸來櫓鞚� 氚滍憸頃� 鞓堨爼鞚措┌, 鞐赴鞐惖鐢 CUE-100 鞁滊Μ歃�, CUE-401, CUE-501鞚� 韽暔霅╇媹雼�. 氚滍憸鞐愳劀电� CUE-501鞐� 雽�頃� Boehringer Ingelheim瓿检潣 斓滉芳 順戨牓鞚� 臧曥“霅橂┌, 鞚吹鐢 鞛愱皜氅挫棴 氚� 鞐检 歆堩櫂 旃橂毳� 鞙勴暅 T靹疙彫 毵り皽 韸轨爼 B靹疙彫 響滌爜 鞝滉卑鞐� 欷戩爯鞚� 霊‰媹雼�. 霛检澊敫� 鞗轨簮鞀ろ姼臧� 鞝滉车霅橂┌, 雲鬼檾氤胳潃 須岇偓 鞗轨偓鞚错姼鞐愳劀 30鞚缄皠 鞎勳勾鞚措笇霅╇媹雼�.
Cue Biopharma (Nasdaq : CUE) a annonc茅 sa participation 脿 une discussion informelle lors de la Citizens Life Sciences Conference 脿 New York le 8 mai 2025. Le PDG Daniel Passeri pr茅sentera de 11h00 脿 11h25 EDT, abordant les avanc茅es des programmes de la plateforme Immuno-STAT鈩�, incluant la s茅rie CUE-100, CUE-401 et CUE-501. La pr茅sentation mettra en lumi猫re leur r茅cent partenariat avec Boehringer Ingelheim pour le CUE-501, ax茅 sur la d茅pl茅tion cibl茅e des cellules B sp茅cifiques m茅di茅e par les cellules T pour le traitement des maladies auto-immunes et inflammatoires. Un webcast en direct sera disponible, et l鈥檈nregistrement sera archiv茅 pendant 30 jours sur le site web de l鈥檈ntreprise.
Cue Biopharma (Nasdaq: CUE) gab bekannt, dass es an einem Fireside-Chat auf der Citizens Life Sciences Conference in New York am 8. Mai 2025 teilnehmen wird. CEO Daniel Passeri wird von 11:00 bis 11:25 Uhr EDT pr盲sentieren und dabei Fortschritte bei den Immuno-STAT鈩�-Plattformprogrammen, einschlie脽lich der CUE-100-Serie, CUE-401 und CUE-501, erl盲utern. Die Pr盲sentation wird die k眉rzlich eingegangene Partnerschaft mit Boehringer Ingelheim f眉r CUE-501 hervorheben, die sich auf die T-Zell-vermittelte gezielte Eliminierung spezifischer B-Zellen zur Behandlung von Autoimmun- und Entz眉ndungskrankheiten konzentriert. Ein Live-Webcast wird verf眉gbar sein, und die Aufzeichnung wird f眉r 30 Tage auf der Website des Unternehmens archiviert.
- None.
- None.
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- 听(狈补蝉诲补辩: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at聽the Citizens Life Sciences Conference聽being held in聽New York,聽May 7-8, 2025.
During the fireside chat, Cue Biopharma will discuss progress on its programs from the Immuno-STAT鈩� platform including the CUE-100 series, CUE-401, and CUE-501, which was recently partnered with Boehringer Ingelheim for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases.
Citizens Life Sciences Conference
Presentation Date:聽Thursday, May 8, 2025
Presentation Time: 11:00 a.m. EDT 鈥撀�11:25 a.m. EDT
Presenter: Daniel Passeri, Chief Executive Officer
Webcast Link:聽
A live and archived webcast of the fireside chat will be available in the News and Publications section of the Company鈥檚 . The webcast will be archived for 30 days.
About聽Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient鈥檚 body. The company鈥檚 proprietary platform, Immuno-STAT鈩� (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body鈥檚 intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in聽Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
For more information please visit聽聽and follow us on聽 and .
Investor Contact
Marie Campinell聽
Senior Director, Corporate Communications
Cue Biopharma, Inc.
Media Contact
Jonathan Pappas
LifeSci Communications
FAQ
When is Cue Biopharma (CUE) presenting at the Citizens Life Sciences Conference 2025?
What will Cue Biopharma discuss during their Citizens Life Sciences Conference presentation?
Who is presenting for Cue Biopharma at the Citizens Life Sciences Conference?
What is the recent partnership between Cue Biopharma (CUE) and Boehringer Ingelheim?
